Sarepta Therapeutics (SRPT) Cash from Financing Activities (2010 - 2026)

Sarepta Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $241000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 98.07% year-over-year to $241000.0; the TTM figure through Mar 2026 stood at -$180.6 million (down 256.83% YoY), while the FY2025 annual figure was -$168.3 million, down 234.88% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $241000.0, up from -$39.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $216.4 million in Q3 2022, with the low at -$117.8 million in Q3 2025.
• The 5-year median for Cash from Financing Activities is $10.7 million (2022), against an average of $18.5 million.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities soared 3567.05% in 2022, then tumbled 956.22% in 2025.
• Sarepta Therapeutics' Cash from Financing Activities stood at $10.7 million in 2022, then tumbled by 81.92% to $1.9 million in 2023, then surged by 2421.41% to $49.0 million in 2024, then slumped by 180.03% to -$39.2 million in 2025, then surged by 100.61% to $241000.0 in 2026.
• Business Quant data shows SRPT's Cash from Financing Activities at $241000.0 in Q1 2026, -$39.2 million in Q4 2025, and -$117.8 million in Q3 2025.